San Diego Startup Scores Fast Track In High-Stakes Fight Against Bipolar Depression

San Diego’s Autobahn Therapeutics is stepping on the gas with its experimental depression drug, landing coveted Fast Track status from the Food and Drug Administration while also rolling out upbeat Phase 2 data from a small bipolar study.

The company said the FDA has granted Fast Track designation for elunetirom, its brain-targeted thyroid-hormone-receptor therapy being developed as an add-on to existing antidepressant regimens. Autobahn also shared topline Phase 2 results last Thursday from an open-label bipolar depression trial, reporting a 16.8-point mean drop on the HAMD-17 scale, a 75% response rate and a 50% remission rate at six weeks in 21 adults.

In a press release, Autobahn said the FDA granted Fast Track status to elunetirom for the adjunctive treatment of depressive episodes tied to bipolar I or II disorder in adults, and described the candidate as an oral, once-daily, brain-penetrant CNS thyroid hormone receptor agonist, according to Autobahn Therapeutics. Fast Track can give drug developers more frequent check-ins with regulators and options such as rolling review, which the agency says can help speed development when a therapy targets a serious condition with an unmet medical need, per the FDA.

What the Phase 2 readout showed

Autobahn released topline results from its AMPLIFY-BD study, reporting a statistically significant 16.8-point mean reduction in HAMD-17 at Week 6 (p<0.001), alongside a 75% response rate and 50% remission rate; the company said symptom improvements appeared as early as Week 2, according to a company release distributed by Business Wire. The AMPLIFY-BD data come from an open-label, adjunctive study in 21 adults, so clinicians and researchers will be waiting on larger, controlled trials before talking about any definitive clinical advance.

Next steps and the regulatory path

Autobahn said it plans to share full AMPLIFY-BD results at a medical conference in the second half of 2026 and expects topline data from its parallel AMPLIFY trial in major depressive disorder in the third quarter of 2026; the company added that it will engage with regulators to assess a potential path to registration, per Autobahn Therapeutics. Those conversations are exactly the kind of early, iterative feedback Fast Track is designed to facilitate, although the designation does not guarantee approval and regulators will expect robust randomized evidence in later-stage trials.

Why San Diego is watching

Headquartered in San Diego, Autobahn has pulled in substantial venture backing; the company closed a $100 million Series C in 2024 and lists major pharma venture arms and institutional investors among its backers, according to a company announcement posted by Business Wire. That funding is earmarked for mid-stage testing of elunetirom and a second CNS candidate as the startup works to turn its early signal into larger, registrational studies.

The upbeat topline readout and the FDA’s Fast Track nod mark early momentum for a relatively small San Diego player, though the real verdict will hinge on how the AMPLIFY program’s randomized, placebo-controlled data shake out. Until then, investors, local biotech watchers and clinicians will be tracking the full dataset and Autobahn’s upcoming regulator meetings closely.